A large phase 3 trial found that adding high-dose vitamin D3 to standard treatment did not significantly delay cancer progression or improve survival among patients with previously untreated metastatic colorectal cancer.
Editorial Note
This article provides educational information about a clinical trial and is not medical advice. Patients should not begin, stop, or change vitamin D supplementation or cancer treatment without speaking with their oncology team.
A Large Phase 3 Trial Tested High-Dose Vitamin D
A major clinical trial found that adding high-dose vitamin D3 to standard treatment did not significantly improve outcomes for patients with previously untreated metastatic colorectal cancer.
The results of the SOLARIS trial were published in JAMA on August 3, 2026.
Researchers enrolled 455 adults whose colorectal cancer had spread to other parts of the body and could not be surgically removed. The study was conducted at 151 academic and community treatment centers across the United States.
Participants received chemotherapy and bevacizumab, a medicine that limits the development of blood vessels supporting tumor growth. They were randomly assigned to receive either high-dose or standard-dose vitamin D3.
The high-dose group initially received 8,000 international units daily before transitioning to 4,000 units per day. The standard-dose group received 400 units daily.
After a median follow-up of approximately 20 months, the researchers found no statistically significant improvement in the trial’s primary outcome.
Cancer Progression Was Not Significantly Delayed
The trial’s main goal was to determine whether high-dose vitamin D could improve progression-free survival.
Progression-free survival measures how long patients remain alive without their cancer worsening. It does not mean that the cancer has disappeared.
Median progression-free survival was 11.8 months in the high-dose group and 10.3 months in the standard-dose group.
Although the numerical result favored the higher dose, the difference was not statistically significant. The study therefore did not provide sufficient evidence that high-dose vitamin D caused a meaningful delay in disease progression.
This distinction is important. A numerical difference between two groups does not automatically establish that one treatment is more effective. Researchers must determine whether the difference is large and consistent enough that it is unlikely to be explained by chance.
Overall Survival Did Not Improve
High-dose vitamin D also did not improve overall survival.
Median overall survival was 25.6 months in the high-dose group and 27 months in the standard-dose group.
The objective response rate was 51% with high-dose vitamin D and 44% with the standard dose. This means a larger percentage of patients in the high-dose group experienced a defined reduction in tumor size.
However, the response-rate difference did not change the trial’s main conclusion. High-dose vitamin D did not significantly improve progression-free survival or extend patients’ lives.
The results do not support adding high-dose vitamin D routinely to standard metastatic colorectal cancer treatment with the expectation that it will improve those outcomes.
Why Researchers Thought Vitamin D Might Help
Scientists have studied possible connections between vitamin D and cancer for many years.
Vitamin D is best known for supporting bone health and helping regulate calcium and phosphorus. It also affects immune activity, inflammation, and cell growth, all of which may be relevant to cancer biology.
Some observational studies have found that people with higher vitamin D levels experience better colorectal cancer outcomes than people with lower levels.
However, observational studies cannot prove that vitamin D caused those differences.
People with higher vitamin D levels may also have better overall health, different diets, more physical activity, greater sun exposure, fewer chronic illnesses, or better access to care.
Cancer itself can also affect nutrition, physical activity, inflammation, and vitamin levels. A low vitamin D level may sometimes reflect poor health rather than directly causing a worse outcome.
Randomized clinical trials are needed to separate these possibilities.
An Earlier Trial Produced Promising Results
The SOLARIS trial followed an earlier phase 2 study known as SUNSHINE.
Published in 2019, SUNSHINE included 139 patients with advanced or metastatic colorectal cancer. It compared high-dose and standard-dose vitamin D alongside chemotherapy.
Median progression-free survival was approximately 13 months in the high-dose group and 11 months in the standard-dose group.
The primary comparison was not statistically significant, but an adjusted analysis suggested that high-dose vitamin D might reduce the risk of progression or death.
Those findings were encouraging enough to justify a larger phase 3 trial.
This is how clinical research is supposed to work. Smaller studies may identify promising treatment signals, but those signals must be tested in larger and more rigorous trials before becoming standard care.
The Larger Trial Did Not Confirm the Earlier Signal
SOLARIS included more patients, more treatment centers, and a design intended to provide a more reliable answer.
The larger trial did not confirm the benefit suggested by the earlier research.
That does not mean the earlier trial was poorly conducted. Smaller studies are more vulnerable to chance findings, imbalances between groups, and treatment effects that appear stronger than they are.
A treatment can look promising in an early trial and then fail to show a clear benefit when tested in a larger and more diverse population.
Negative results are still valuable because they help prevent patients from receiving treatments that do not provide the expected benefit.
Both Groups Received Vitamin D
The trial did not compare high-dose vitamin D with no vitamin D.
Both groups received vitamin D3. The difference was the dose.
The standard-dose group received 400 international units per day. The high-dose group received 8,000 units during an initial loading period and then 4,000 units daily.
The trial therefore does not show that vitamin D has no role in health or that patients should ignore a diagnosed deficiency.
It tested a narrower question: whether substantially increasing the dose would improve outcomes when added to standard treatment for metastatic colorectal cancer.
For the overall patient population studied, it did not.
The Results Do Not Apply to Every Use of Vitamin D
The SOLARIS findings should not be interpreted more broadly than the evidence allows.
The trial involved adults with previously untreated, unresectable metastatic colorectal cancer who were receiving specific combinations of chemotherapy and bevacizumab.
It did not determine whether vitamin D prevents colorectal cancer.
It did not evaluate every cancer stage, molecular subtype, treatment combination, or reason a physician might prescribe vitamin D.
It also did not show that treating a medically diagnosed vitamin D deficiency is unnecessary.
Vitamin D may still be recommended for bone health or to correct low blood levels. Those are different medical questions from whether high-dose supplementation makes metastatic colorectal cancer treatment more effective.
High Doses Are Not Automatically Better
Vitamin supplements are often viewed as harmless because they are widely available without a prescription.
However, a nutrient the body needs in normal amounts is not automatically more beneficial at a higher dose.
Vitamin D is fat-soluble, meaning it can accumulate in the body. Excessive intake may raise calcium levels and contribute to nausea, weakness, confusion, dehydration, kidney stones, kidney damage, or abnormal heart rhythms.
Cancer patients may also have health conditions or take medicines that affect whether a supplement is appropriate.
The SOLARIS trial used high-dose vitamin D under medical supervision. Its dosing should not be treated as a recommendation for unsupervised use.
Patients should tell their healthcare team about every vitamin, mineral, herbal product, and supplement they take.
Safety Outcomes Were Similar
The rates of severe adverse events were generally similar between the high-dose and standard-dose groups.
That suggests the high-dose regimen did not cause a major overall increase in serious toxicity during the trial.
However, a treatment must provide enough benefit to justify its cost, monitoring, inconvenience, and potential risks.
A therapy can be reasonably well tolerated and still not be useful if it does not improve cancer control or survival.
Safety and effectiveness must therefore be evaluated separately.
Why the Findings Matter
Many cancer patients use dietary supplements.
Some take them to correct a diagnosed deficiency. Others hope to strengthen immunity, reduce side effects, increase energy, slow cancer growth, or gain a greater sense of control.
Those motivations are understandable, but supplements are not evaluated under the same approval standards as prescription cancer treatments.
A biological theory, observational association, laboratory study, or small clinical trial can make a supplement appear promising. None of those forms of evidence can replace a well-designed phase 3 trial when determining whether a treatment improves patient outcomes.
SOLARIS provides a clearer answer for one specific use of high-dose vitamin D.
Negative Trials Still Advance Medical Knowledge
A clinical trial does not fail simply because the treatment being tested does not work as hoped.
SOLARIS answered an important medical question involving hundreds of patients and more than 150 treatment centers.
It showed that the signal from earlier research was not strong enough to support routine high-dose vitamin D as part of standard metastatic colorectal cancer treatment.
That information can help patients and physicians avoid adding an intervention without proven benefit.
Future studies may still examine whether vitamin D has different effects in patients with severe deficiency, particular molecular subtypes, earlier-stage disease, or other treatment combinations.
Those possibilities require new evidence and should not be assumed from the present study.
What Patients Should Take From the Study
Patients should not stop medically recommended vitamin D because of this trial.
The results do not mean that vitamin D is unimportant for bone health or that physicians should not treat a deficiency.
They mean that the high-dose regimen tested in SOLARIS did not make standard treatment more effective for the overall group of patients with previously untreated metastatic colorectal cancer.
Anyone receiving cancer care should discuss supplementation with an oncologist, pharmacist, dietitian, or other qualified healthcare professional.
That discussion should consider the reason for taking vitamin D, the dose, blood-test results, kidney health, calcium levels, other medicines, and the patient’s overall treatment plan.
Cancer treatment should not be changed based on a headline, social-media post, or supplement advertisement.
Key Takeaways
The phase 3 SOLARIS trial enrolled 455 adults with previously untreated, unresectable metastatic colorectal cancer at 151 U.S. treatment centers.
Participants received chemotherapy and bevacizumab along with either high-dose or standard-dose vitamin D3.
Median progression-free survival was 11.8 months with high-dose vitamin D and 10.3 months with the standard dose. The difference was not statistically significant.
Median overall survival was 25.6 months in the high-dose group and 27 months in the standard-dose group.
The findings did not confirm the treatment signal reported in the earlier SUNSHINE phase 2 trial.
The study does not mean vitamin D has no role in health or that medically diagnosed deficiencies should not be treated.
Patients should not begin high-dose supplementation or change cancer treatment without guidance from their healthcare team.
Frequently Asked Questions
Did high-dose vitamin D improve metastatic colorectal cancer survival?
No. The trial did not find a significant improvement in progression-free survival or overall survival.
Did patients receive vitamin D instead of chemotherapy?
No. All participants received chemotherapy and bevacizumab. Vitamin D was studied as an additional treatment.
Was the comparison group given a placebo?
No. The standard-dose group received 400 international units of vitamin D3 per day.
Does this mean vitamin D is unhealthy?
No. Vitamin D remains important for bone health and other functions. The study addressed whether a high dose improved outcomes in a specific cancer-treatment setting.
Should cancer patients stop taking vitamin D?
Patients should not stop or change supplements without speaking with their healthcare team. Some people may need vitamin D to treat a deficiency or protect bone health.
Final Thoughts
The SOLARIS trial provides an important reminder that a promising idea is not the same as a proven treatment.
Earlier research created reasonable hope that high-dose vitamin D might improve outcomes for patients with metastatic colorectal cancer. That possibility deserved to be tested in a larger trial.
The larger trial did not confirm a meaningful benefit.
Adding high-dose vitamin D to standard chemotherapy and bevacizumab did not significantly delay cancer progression or extend survival.
That result may be disappointing, but it is useful.
Reliable medical research protects patients not only by identifying effective treatments but also by showing when an additional intervention does not deliver the expected benefit.
Vitamin D remains important for health, and treating a deficiency may still be appropriate. However, patients should not assume that taking more will improve cancer outcomes.
The safest approach is to base supplementation and treatment decisions on individual medical needs, laboratory findings, and guidance from the patient’s healthcare team.
Support New To Education
New To Education publishes independent reporting and analysis about health research, education, technology, employment, business, science, and developments affecting families and communities.
Readers can support this work by sharing the article, subscribing to New To Education updates, joining the New To Education community, or exploring the educational and professional services available through the platform.
Related Articles
New Alzheimer’s Drug Trial Shows Why Negative Research Results Still Matter
New Study Finds That Sitting for More Than 30 Minutes at a Time May Increase Cancer Risk
New Study Links Coffee to Lower Risks of Liver Scarring, Cancer and Liver-Related Death
AI Drug Discovery Reaches a Major Test With Insilico Medicine’s Phase III Trial
Sources
JAMA — Addition of High-Dose Vitamin D3 to Standard Treatment for Metastatic Colorectal Cancer
ClinicalTrials.gov — SOLARIS Trial, NCT04094688
National Cancer Institute — SOLARIS Phase 3 Trial Description
JAMA — SUNSHINE Phase 2 Randomized Clinical Trial
